CSPC Pharma Secures Shareholder Consent to Divest 30.07% Stake in Beijing Guoxin Huijin

Bulletin Express04-08

CSPC Pharmaceutical Group Limited (CSPC Pharma) reported that shareholders of the vendor involved in its connected transaction have formally approved the disposal of a 30.0704% equity interest in Beijing Guoxin Huijin Co., Ltd.

The approval, granted at the vendor’s shareholders’ meeting on 8 April 2026, satisfies a key condition precedent in the Equity Transfer Agreement first disclosed on 26 February 2026. With this endorsement, the disposal will now move toward completion in accordance with the agreement’s stipulated terms and conditions.

Categorised as a connected transaction under Hong Kong Listing Rules, the divestment underscores CSPC Pharma’s ongoing portfolio adjustments. No further financial details—such as consideration amount, expected gain or timetable—were provided in the latest filing.

The board of CSPC Pharma is chaired by Cai Dong Chen and currently comprises 12 executive directors and six independent non-executive directors. The company affirmed that all requisite procedural steps for the transaction have been met following the shareholder vote.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104821128?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-08 22:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104821128","market":"us","top_or_hot":-1,"title":"CSPC Pharma Secures Shareholder Consent to Divest 30.07% Stake in Beijing Guoxin Huijin","media":"Bulletin Express","content":"<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) reported that shareholders of the vendor involved in its connected transaction have formally approved the disposal of a 30.0704% equity interest in Beijing Guoxin Huijin Co., Ltd.</p>\n<p>The approval, granted at the vendor’s shareholders’ meeting on 8 April 2026, satisfies a key condition precedent in the Equity Transfer Agreement first disclosed on 26 February 2026. With this endorsement, the disposal will now move toward completion in accordance with the agreement’s stipulated terms and conditions.</p>\n<p>Categorised as a connected transaction under Hong Kong Listing Rules, the divestment underscores CSPC Pharma’s ongoing portfolio adjustments. No further financial details—such as consideration amount, expected gain or timetable—were provided in the latest filing.</p>\n<p>The board of CSPC Pharma is chaired by Cai Dong Chen and currently comprises 12 executive directors and six independent non-executive directors. The company affirmed that all requisite procedural steps for the transaction have been met following the shareholder vote.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Pharma Secures Shareholder Consent to Divest 30.07% Stake in Beijing Guoxin Huijin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Pharma Secures Shareholder Consent to Divest 30.07% Stake in Beijing Guoxin Huijin\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-08 22:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Pharmaceutical Group Limited (CSPC Pharma) reported that shareholders of the vendor involved in its connected transaction have formally approved the disposal of a 30.0704% equity interest in Beijing Guoxin Huijin Co., Ltd.</p>\n<p>The approval, granted at the vendor’s shareholders’ meeting on 8 April 2026, satisfies a key condition precedent in the Equity Transfer Agreement first disclosed on 26 February 2026. With this endorsement, the disposal will now move toward completion in accordance with the agreement’s stipulated terms and conditions.</p>\n<p>Categorised as a connected transaction under Hong Kong Listing Rules, the divestment underscores CSPC Pharma’s ongoing portfolio adjustments. No further financial details—such as consideration amount, expected gain or timetable—were provided in the latest filing.</p>\n<p>The board of CSPC Pharma is chaired by Cai Dong Chen and currently comprises 12 executive directors and six independent non-executive directors. The company affirmed that all requisite procedural steps for the transaction have been met following the shareholder vote.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1104821128","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104821128","pubTimestamp":1775658119,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CSPC Pharmaceutical Group Limited (CSPC Pharma) reported that shareholders of the vendor involved in its connected transaction have formally approved the disposal of a 30.0704% equity interest in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团获股东同意剥离北京国鑫汇金30.07%股权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC Pharmaceutical Group Limited (CSPC Pharma) reported that shareholders of the vendor involved in its connected transaction have formally approved the disposal of a 30.0704% equity interest in Beijing Guoxin Huijin Co., Ltd.\nThe approval, granted at the vendor’s shareholders’ meeting on 8 April 2026, satisfies a key condition precedent in the Equity Transfer Agreement first disclosed on 26 February 2026. With this endorsement, the disposal will now move toward completion in accordance with the agreement’s stipulated terms and conditions.\nCategorised as a connected transaction under Hong Kong Listing Rules, the divestment underscores CSPC Pharma’s ongoing portfolio adjustments. No further financial details—such as consideration amount, expected gain or timetable—were provided in the latest filing.\nThe board of CSPC Pharma is chaired by Cai Dong Chen and currently comprises 12 executive directors and six independent non-executive directors. The company affirmed that all requisite procedural steps for the transaction have been met following the shareholder vote.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104821128","isCrawlerRequest":true}